Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
Hand-out
Press Releases
Bambusa Therapeutics  
February 14, 2025

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed

avatar profile Olean Times Herald

Olean Times Herald


Local & Social